New Two-Pronged attack on advanced cancers begins human testing
NCT ID NCT07446725
Summary
This early-stage study is testing a new combination of two oral drugs, GH55 and GH21, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if blocking two specific cancer growth pathways at once is safe and can help control the disease. The study will first find the safest dose and then see how well the combination works in about 152 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Goboard Cancer Hospital
Shanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.